The different roles of ER subtypes in cancer biology and therapy

Key Points Oestrogen receptor (ER) subtypes (ERα and ERβ) influence the development and progression of hormone-related cancers by exerting distinct biological functions. ERα is associated with aberrant proliferation, inflammation and the development of malignancy. ERβ seems to oppose ERα actions on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Cancer 2011-08, Vol.11 (8), p.597-608
Hauptverfasser: Thomas, Christoforos, Gustafsson, Jan-Åke
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 608
container_issue 8
container_start_page 597
container_title Nature reviews. Cancer
container_volume 11
creator Thomas, Christoforos
Gustafsson, Jan-Åke
description Key Points Oestrogen receptor (ER) subtypes (ERα and ERβ) influence the development and progression of hormone-related cancers by exerting distinct biological functions. ERα is associated with aberrant proliferation, inflammation and the development of malignancy. ERβ seems to oppose ERα actions on cell proliferation by modulating the expression of many ERα-regulated genes and exhibits antimigratory and anti-invasive properties in cancer cells. Multiple factors affect the ER-mediated regulation of gene expression and may account for the adverse and beneficial effects of oestrogens and anti-oestrogens. Both ER genomic and non-genomic actions often converge at certain regulatory sites of the adjacent ER-responsive genes. The final gene and the subsequent cancer biological responses may vary depending on the combination of transcription factors; the ratio and the cellular localization of ERα and ERβ; the expression levels of various co-regulators and signal transduction components; and the nature of extracellular stimuli. These variables are altered during cancer transformation and are divergent in different cancer cells. Owing to the practical limitations in detection, only a few truncated ERα and ERβ variant isoforms have been examined in tumour samples and correlated with clinical outcome. Some of these variants are localized in the cytoplasm and plasma membrane, show variable expression in cancer tissues and influence cancer progression and response to therapy either through genomic pathways by modulating the activity of wild-type ERs or by interacting with the membrane and cytoplasmic signalling cascade. Perturbation of ER subtype-specific expression has been detected in different stages of various types of cancer, with the levels of ERα and ERβ declining in most cancers as the disease develops. The hypermethylation of the ER promoters, microRNAs that target the ER mRNAs and increased proteasomal degradation are among the factors that are responsible for the reduced levels of ERs in cancer tissues. ERα is the principal biomarker for the response of breast cancers to endocrine therapy, and its truncated isoform ERα-36 seems to confer resistance to tamoxifen. On-going research is trying to fully clarify the prognostic and predictive role of ERβ. So far, it seems that the nuclear wild-type ERβ complements ERα in predicting response to endocrine therapy and is associated with better overall outcome and the metastatic potential of breast and prostate cancer.
doi_str_mv 10.1038/nrc3093
format Article
fullrecord <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_542943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A263349430</galeid><sourcerecordid>A263349430</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-989530c74e78d830ab5302242b09eb574372b458ca0d2a755091ea063bf0bbaa3</originalsourceid><addsrcrecordid>eNptkt9rFDEQx4MotlbxP5CgoL5sza_dZN8spdpCQZAKvoUkO3uXupesyS5y_705bj3bUvKQmclnZvhOBqHXlJxSwtWnkBwnLX-CjqmQoqKyUU8Pdv3zCL3I-ZYQ2lBJn6MjRqVsCSXH6PPNGnDn-x4ShAmnOEDGsccX33Ge7bQdi-sDdiY4SNj6OMTVFpvQ4WkNyYzbl-hZb4YMr5b7BP34cnFzflldf_t6dX52XTkhm6lqVVtz4qQAqTrFibHFZUwwS1qwtRRcMitq5QzpmJF1TVoKhjTc9sRaY_gJqvZ18x8YZ6vH5DcmbXU0Xi-hX8UCXQvWCl74D3t-TPH3DHnSG58dDIMJEOeslVSKUSJlId8-IG_jnEIRs4MawRpOCvRuD63MANqHPk7JuF1JfVYALkrPHXX6CFVOBxvvYoDel_i9hPd3EtZghmmd4zBPPoZ8H1zkuBRzTtAfBkCJ3q2AXlagkG8WObPdQHfg_v15AT4ukyxPYQXpv96Htf4CxYa08w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878642630</pqid></control><display><type>article</type><title>The different roles of ER subtypes in cancer biology and therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Thomas, Christoforos ; Gustafsson, Jan-Åke</creator><creatorcontrib>Thomas, Christoforos ; Gustafsson, Jan-Åke</creatorcontrib><description>Key Points Oestrogen receptor (ER) subtypes (ERα and ERβ) influence the development and progression of hormone-related cancers by exerting distinct biological functions. ERα is associated with aberrant proliferation, inflammation and the development of malignancy. ERβ seems to oppose ERα actions on cell proliferation by modulating the expression of many ERα-regulated genes and exhibits antimigratory and anti-invasive properties in cancer cells. Multiple factors affect the ER-mediated regulation of gene expression and may account for the adverse and beneficial effects of oestrogens and anti-oestrogens. Both ER genomic and non-genomic actions often converge at certain regulatory sites of the adjacent ER-responsive genes. The final gene and the subsequent cancer biological responses may vary depending on the combination of transcription factors; the ratio and the cellular localization of ERα and ERβ; the expression levels of various co-regulators and signal transduction components; and the nature of extracellular stimuli. These variables are altered during cancer transformation and are divergent in different cancer cells. Owing to the practical limitations in detection, only a few truncated ERα and ERβ variant isoforms have been examined in tumour samples and correlated with clinical outcome. Some of these variants are localized in the cytoplasm and plasma membrane, show variable expression in cancer tissues and influence cancer progression and response to therapy either through genomic pathways by modulating the activity of wild-type ERs or by interacting with the membrane and cytoplasmic signalling cascade. Perturbation of ER subtype-specific expression has been detected in different stages of various types of cancer, with the levels of ERα and ERβ declining in most cancers as the disease develops. The hypermethylation of the ER promoters, microRNAs that target the ER mRNAs and increased proteasomal degradation are among the factors that are responsible for the reduced levels of ERs in cancer tissues. ERα is the principal biomarker for the response of breast cancers to endocrine therapy, and its truncated isoform ERα-36 seems to confer resistance to tamoxifen. On-going research is trying to fully clarify the prognostic and predictive role of ERβ. So far, it seems that the nuclear wild-type ERβ complements ERα in predicting response to endocrine therapy and is associated with better overall outcome and the metastatic potential of breast and prostate cancer. The cytoplasmic ERβ2 (also known as ERβcx) isoform correlates with worse survival and metastatic phenotype. Insights into the mechanisms of ER action and regulation have suggested possible therapeutic approaches for hormone-related cancers. The development of selective ERα and ERβ agonists and antagonists, and alternative strategies that target the ER signalling beyond the ligand-binding activity, including as targets components of growth factor signalling, methylases, ubiquitin ligases, and chaperones are under investigation. Perturbation of oestrogen receptor (ER) subtype-specific expression has been detected in various types of cancer, and these differences correlate with the clinical outcome. The selective restoration or ablation of their activity is one of the major therapeutic approaches for hormone-dependent cancers. By eliciting distinct transcriptional responses, the oestrogen receptors (ERs) ERα and ERβ exert opposite effects on cellular processes that include proliferation, apoptosis and migration and that differentially influence the development and the progression of cancer. Perturbation of ER subtype-specific expression has been detected in various types of cancer, and the differences in the expression of ERs are correlated with the clinical outcome. The changes in the bioavailability of ERs in tumours, together with their specific biological functions, promote the selective restoration of their activity as one of the major therapeutic approaches for hormone-dependent cancers.</description><identifier>ISSN: 1474-175X</identifier><identifier>EISSN: 1474-1768</identifier><identifier>DOI: 10.1038/nrc3093</identifier><identifier>PMID: 21779010</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1059/602 ; 631/67/68 ; 631/80/86/2363 ; Animals ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Cancer cells ; Cancer Research ; Care and treatment ; Development and progression ; Estrogen ; Estrogen Receptor alpha - physiology ; Estrogen Receptor beta - physiology ; Gene expression ; Genetic aspects ; Humans ; Neoplasms - drug therapy ; Neoplasms - physiopathology ; Physiological aspects ; Prognosis ; Protein Isoforms ; Receptors ; review-article</subject><ispartof>Nature reviews. Cancer, 2011-08, Vol.11 (8), p.597-608</ispartof><rights>Springer Nature Limited 2011</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Aug 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-989530c74e78d830ab5302242b09eb574372b458ca0d2a755091ea063bf0bbaa3</citedby><cites>FETCH-LOGICAL-c476t-989530c74e78d830ab5302242b09eb574372b458ca0d2a755091ea063bf0bbaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrc3093$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrc3093$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21779010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:122969704$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Christoforos</creatorcontrib><creatorcontrib>Gustafsson, Jan-Åke</creatorcontrib><title>The different roles of ER subtypes in cancer biology and therapy</title><title>Nature reviews. Cancer</title><addtitle>Nat Rev Cancer</addtitle><addtitle>Nat Rev Cancer</addtitle><description>Key Points Oestrogen receptor (ER) subtypes (ERα and ERβ) influence the development and progression of hormone-related cancers by exerting distinct biological functions. ERα is associated with aberrant proliferation, inflammation and the development of malignancy. ERβ seems to oppose ERα actions on cell proliferation by modulating the expression of many ERα-regulated genes and exhibits antimigratory and anti-invasive properties in cancer cells. Multiple factors affect the ER-mediated regulation of gene expression and may account for the adverse and beneficial effects of oestrogens and anti-oestrogens. Both ER genomic and non-genomic actions often converge at certain regulatory sites of the adjacent ER-responsive genes. The final gene and the subsequent cancer biological responses may vary depending on the combination of transcription factors; the ratio and the cellular localization of ERα and ERβ; the expression levels of various co-regulators and signal transduction components; and the nature of extracellular stimuli. These variables are altered during cancer transformation and are divergent in different cancer cells. Owing to the practical limitations in detection, only a few truncated ERα and ERβ variant isoforms have been examined in tumour samples and correlated with clinical outcome. Some of these variants are localized in the cytoplasm and plasma membrane, show variable expression in cancer tissues and influence cancer progression and response to therapy either through genomic pathways by modulating the activity of wild-type ERs or by interacting with the membrane and cytoplasmic signalling cascade. Perturbation of ER subtype-specific expression has been detected in different stages of various types of cancer, with the levels of ERα and ERβ declining in most cancers as the disease develops. The hypermethylation of the ER promoters, microRNAs that target the ER mRNAs and increased proteasomal degradation are among the factors that are responsible for the reduced levels of ERs in cancer tissues. ERα is the principal biomarker for the response of breast cancers to endocrine therapy, and its truncated isoform ERα-36 seems to confer resistance to tamoxifen. On-going research is trying to fully clarify the prognostic and predictive role of ERβ. So far, it seems that the nuclear wild-type ERβ complements ERα in predicting response to endocrine therapy and is associated with better overall outcome and the metastatic potential of breast and prostate cancer. The cytoplasmic ERβ2 (also known as ERβcx) isoform correlates with worse survival and metastatic phenotype. Insights into the mechanisms of ER action and regulation have suggested possible therapeutic approaches for hormone-related cancers. The development of selective ERα and ERβ agonists and antagonists, and alternative strategies that target the ER signalling beyond the ligand-binding activity, including as targets components of growth factor signalling, methylases, ubiquitin ligases, and chaperones are under investigation. Perturbation of oestrogen receptor (ER) subtype-specific expression has been detected in various types of cancer, and these differences correlate with the clinical outcome. The selective restoration or ablation of their activity is one of the major therapeutic approaches for hormone-dependent cancers. By eliciting distinct transcriptional responses, the oestrogen receptors (ERs) ERα and ERβ exert opposite effects on cellular processes that include proliferation, apoptosis and migration and that differentially influence the development and the progression of cancer. Perturbation of ER subtype-specific expression has been detected in various types of cancer, and the differences in the expression of ERs are correlated with the clinical outcome. The changes in the bioavailability of ERs in tumours, together with their specific biological functions, promote the selective restoration of their activity as one of the major therapeutic approaches for hormone-dependent cancers.</description><subject>631/67/1059/602</subject><subject>631/67/68</subject><subject>631/80/86/2363</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Cancer cells</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Development and progression</subject><subject>Estrogen</subject><subject>Estrogen Receptor alpha - physiology</subject><subject>Estrogen Receptor beta - physiology</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - physiopathology</subject><subject>Physiological aspects</subject><subject>Prognosis</subject><subject>Protein Isoforms</subject><subject>Receptors</subject><subject>review-article</subject><issn>1474-175X</issn><issn>1474-1768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkt9rFDEQx4MotlbxP5CgoL5sza_dZN8spdpCQZAKvoUkO3uXupesyS5y_705bj3bUvKQmclnZvhOBqHXlJxSwtWnkBwnLX-CjqmQoqKyUU8Pdv3zCL3I-ZYQ2lBJn6MjRqVsCSXH6PPNGnDn-x4ShAmnOEDGsccX33Ge7bQdi-sDdiY4SNj6OMTVFpvQ4WkNyYzbl-hZb4YMr5b7BP34cnFzflldf_t6dX52XTkhm6lqVVtz4qQAqTrFibHFZUwwS1qwtRRcMitq5QzpmJF1TVoKhjTc9sRaY_gJqvZ18x8YZ6vH5DcmbXU0Xi-hX8UCXQvWCl74D3t-TPH3DHnSG58dDIMJEOeslVSKUSJlId8-IG_jnEIRs4MawRpOCvRuD63MANqHPk7JuF1JfVYALkrPHXX6CFVOBxvvYoDel_i9hPd3EtZghmmd4zBPPoZ8H1zkuBRzTtAfBkCJ3q2AXlagkG8WObPdQHfg_v15AT4ukyxPYQXpv96Htf4CxYa08w</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Thomas, Christoforos</creator><creator>Gustafsson, Jan-Åke</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20110801</creationdate><title>The different roles of ER subtypes in cancer biology and therapy</title><author>Thomas, Christoforos ; Gustafsson, Jan-Åke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-989530c74e78d830ab5302242b09eb574372b458ca0d2a755091ea063bf0bbaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/67/1059/602</topic><topic>631/67/68</topic><topic>631/80/86/2363</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Cancer cells</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Development and progression</topic><topic>Estrogen</topic><topic>Estrogen Receptor alpha - physiology</topic><topic>Estrogen Receptor beta - physiology</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - physiopathology</topic><topic>Physiological aspects</topic><topic>Prognosis</topic><topic>Protein Isoforms</topic><topic>Receptors</topic><topic>review-article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Christoforos</creatorcontrib><creatorcontrib>Gustafsson, Jan-Åke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Nature reviews. Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Christoforos</au><au>Gustafsson, Jan-Åke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The different roles of ER subtypes in cancer biology and therapy</atitle><jtitle>Nature reviews. Cancer</jtitle><stitle>Nat Rev Cancer</stitle><addtitle>Nat Rev Cancer</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>11</volume><issue>8</issue><spage>597</spage><epage>608</epage><pages>597-608</pages><issn>1474-175X</issn><eissn>1474-1768</eissn><abstract>Key Points Oestrogen receptor (ER) subtypes (ERα and ERβ) influence the development and progression of hormone-related cancers by exerting distinct biological functions. ERα is associated with aberrant proliferation, inflammation and the development of malignancy. ERβ seems to oppose ERα actions on cell proliferation by modulating the expression of many ERα-regulated genes and exhibits antimigratory and anti-invasive properties in cancer cells. Multiple factors affect the ER-mediated regulation of gene expression and may account for the adverse and beneficial effects of oestrogens and anti-oestrogens. Both ER genomic and non-genomic actions often converge at certain regulatory sites of the adjacent ER-responsive genes. The final gene and the subsequent cancer biological responses may vary depending on the combination of transcription factors; the ratio and the cellular localization of ERα and ERβ; the expression levels of various co-regulators and signal transduction components; and the nature of extracellular stimuli. These variables are altered during cancer transformation and are divergent in different cancer cells. Owing to the practical limitations in detection, only a few truncated ERα and ERβ variant isoforms have been examined in tumour samples and correlated with clinical outcome. Some of these variants are localized in the cytoplasm and plasma membrane, show variable expression in cancer tissues and influence cancer progression and response to therapy either through genomic pathways by modulating the activity of wild-type ERs or by interacting with the membrane and cytoplasmic signalling cascade. Perturbation of ER subtype-specific expression has been detected in different stages of various types of cancer, with the levels of ERα and ERβ declining in most cancers as the disease develops. The hypermethylation of the ER promoters, microRNAs that target the ER mRNAs and increased proteasomal degradation are among the factors that are responsible for the reduced levels of ERs in cancer tissues. ERα is the principal biomarker for the response of breast cancers to endocrine therapy, and its truncated isoform ERα-36 seems to confer resistance to tamoxifen. On-going research is trying to fully clarify the prognostic and predictive role of ERβ. So far, it seems that the nuclear wild-type ERβ complements ERα in predicting response to endocrine therapy and is associated with better overall outcome and the metastatic potential of breast and prostate cancer. The cytoplasmic ERβ2 (also known as ERβcx) isoform correlates with worse survival and metastatic phenotype. Insights into the mechanisms of ER action and regulation have suggested possible therapeutic approaches for hormone-related cancers. The development of selective ERα and ERβ agonists and antagonists, and alternative strategies that target the ER signalling beyond the ligand-binding activity, including as targets components of growth factor signalling, methylases, ubiquitin ligases, and chaperones are under investigation. Perturbation of oestrogen receptor (ER) subtype-specific expression has been detected in various types of cancer, and these differences correlate with the clinical outcome. The selective restoration or ablation of their activity is one of the major therapeutic approaches for hormone-dependent cancers. By eliciting distinct transcriptional responses, the oestrogen receptors (ERs) ERα and ERβ exert opposite effects on cellular processes that include proliferation, apoptosis and migration and that differentially influence the development and the progression of cancer. Perturbation of ER subtype-specific expression has been detected in various types of cancer, and the differences in the expression of ERs are correlated with the clinical outcome. The changes in the bioavailability of ERs in tumours, together with their specific biological functions, promote the selective restoration of their activity as one of the major therapeutic approaches for hormone-dependent cancers.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21779010</pmid><doi>10.1038/nrc3093</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1474-175X
ispartof Nature reviews. Cancer, 2011-08, Vol.11 (8), p.597-608
issn 1474-175X
1474-1768
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_542943
source MEDLINE; SpringerLink Journals; Nature Journals Online
subjects 631/67/1059/602
631/67/68
631/80/86/2363
Animals
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer cells
Cancer Research
Care and treatment
Development and progression
Estrogen
Estrogen Receptor alpha - physiology
Estrogen Receptor beta - physiology
Gene expression
Genetic aspects
Humans
Neoplasms - drug therapy
Neoplasms - physiopathology
Physiological aspects
Prognosis
Protein Isoforms
Receptors
review-article
title The different roles of ER subtypes in cancer biology and therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T11%3A01%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20different%20roles%20of%20ER%20subtypes%20in%20cancer%20biology%20and%20therapy&rft.jtitle=Nature%20reviews.%20Cancer&rft.au=Thomas,%20Christoforos&rft.date=2011-08-01&rft.volume=11&rft.issue=8&rft.spage=597&rft.epage=608&rft.pages=597-608&rft.issn=1474-175X&rft.eissn=1474-1768&rft_id=info:doi/10.1038/nrc3093&rft_dat=%3Cgale_swepu%3EA263349430%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=878642630&rft_id=info:pmid/21779010&rft_galeid=A263349430&rfr_iscdi=true